Search for: "MAJOR PHARMACEUTICALS"
Results 221 - 240
of 4,369
Sort by Relevance
|
Sort by Date
4 May 2023, 7:48 am
From 2013 to 2019, Mallinson estimates annual licensing revenues of five major Western SEP holders to be stable at USD 10-11 billion. [read post]
27 Apr 2023, 2:43 pm
The SEPs Regulation Proposal indicates the European Commission’s desire to establish four major requirements for SEPs holders and implementers. [read post]
27 Apr 2023, 5:50 am
But the reality is that Chinese firms are the only major purchasers of machines to make advanced semiconductors whose applications for EU export licenses will be denied. [read post]
26 Apr 2023, 7:00 am
Founded in 1980, the firm pursues healthcare investments in the provider services, life sciences/pharmaceutical industry, hospitals/major facilities and non-reimbursement industries. [read post]
21 Apr 2023, 9:05 pm
And patents play a major role in explaining that price difference. [read post]
21 Apr 2023, 1:00 am
As a result, most patent coverage, even if obtained, was not renewed except in a few major countries. [read post]
19 Apr 2023, 12:45 am
It is unrealistic to expect implementers to have licensing agreements in place with all major SEP holders before implementing a standard, especially device manufacturers who have no knowledge of the standard. [read post]
18 Apr 2023, 5:35 am
Vital Pharmaceuticals, Inc., 2023 WL 2918724, No. [read post]
‘Restricting competencies Milan as third seat central division Unified Patent Court is unacceptable’
17 Apr 2023, 9:13 am
(…) the relationship between the three main seats – if indeed there are to be three – is a major question that all interested parties will want answers to before they start bringing their disputes to the court. [read post]
10 Apr 2023, 9:01 pm
At the close of business on Good Friday, federal judge Matthew Kacsmaryk released a ruling in Alliance for Hippocratic Medicine vs. [read post]
4 Apr 2023, 11:55 am
” Although a majority of the judges on the appellate panel for the California Court of Appeal concluded that Prop 22 violated the separation of powers principles by limiting lawmakers’ ability to enact amendments, such as allowing gig workers to unionize, the panel severed that portion of the voter-backed initiative and “allow[ed] the rest of Proposition 22 to remain in effect, as voters indicated they wished. [read post]
4 Apr 2023, 7:00 am
This post uses topic modeling, a natural language processing algorithm I’ve used in previous blog posts, including here[1] and here[2], to discern the major topics of these requests. [read post]
31 Mar 2023, 5:44 am
The vast differences between the products involved in these cases — software, vehicles, and pharmaceuticals — illustrate the breadth of products liability law. [read post]
31 Mar 2023, 3:10 am
IMT argued that its sign would be associated with Mount Ararat or at least some mountain, but the GC considered that it would be seen just an abstract triangular geometric shape, at least by the majority of the relevant public. [read post]
30 Mar 2023, 7:10 am
Nevertheless, the majority of providers take on those risks to be reimbursed for the ASP, as this price is generally high. [read post]
30 Mar 2023, 7:10 am
Nevertheless, the majority of providers take on those risks to be reimbursed for the ASP, as this price is generally high. [read post]
29 Mar 2023, 12:09 pm
” Today genus patents are particularly common in pharmaceutical, chemical, and biotech development. [read post]
29 Mar 2023, 8:59 am
Within healthcare, the firm targets the provider services, hospitals/major facilities, life sciences/pharmaceutical and non-reimbursement industries. [read post]
29 Mar 2023, 2:50 am
This decision saw “their Lordships split in opinion“, with the majority voting that “the specification must disclose some reason for supposing that the implied assertion of efficacy in the claim is true“. [read post]
27 Mar 2023, 9:01 pm
This year-end update provides an overview of the major developments in federal and state securities litigation since our last update in September 2022: The Supreme Court is set to hear a blockbuster case that will shape whether and how shareholders can establish standing to bring claims under Sections 11 and 12 of the Securities Act when a company sells its shares in a direct listing. [read post]
